Biosimilar Insights

31. White Raven's Accelerated Path To GMP Certification 4/28/2025

    CDMO White Raven achieved GMP certification using an innovative aseptic filling solution in just 18 months. Discover how meticulous planning and collaboration set a new industry standard for efficiency.

32. Service Solutions Designed To Help You Gain Speed To Clinic And Market 4/28/2025

    Discover how speed, cost, and regulatory acceptance impact drug manufacturing, as well as learn about aseptic filling challenges and how innovative services can enhance your efficiency and compliance.

33. What Threatens Biosimilars, How Partnerships Protect Them 4/25/2025

    Bioprocess Online Live’s panel discussion Impact Of The Biosimilars Boom wraps up with a discussion about biosimilar development partnership strategy before reflection on a poll of the audience’s perceived threats to biosimilar strategy. Biosimilars Forum Executive Director Juliana Reed and Celltrion VP of Medical Affairs Hetal Patel, PharmD, MBA offer their closing remarks on continued education, alignment across the healthcare ecosystem, and the shared goal of improving access and affordability through biosimilars.

34. Biosimilars Cost Control And IP Protection 4/25/2025

    In addition to reflecting on a live poll of our audience, Kashiv Biosciences' Associate VP Kaushal Joshi discusses IP protection and cost control in biosimilars development and addresses audience questions on reference batches and assay development in this segment of the Bioprocess Online Live panel discussion Impact Of The Biosimilars Boom.

35. Market And Policy Dynamics Impacting Biosimilars 4/25/2025

    In this segment of the Bioprocess Online Live panel discussion Impact Of The Biosimilars Boom, Biosimilars Forum Executive Director Juliana Reed and Celltrion VP of Medical Affairs Hetal Patel, PharmD, MBA address the role of policy and legislation in biosimilar adoption. Market dynamics, competition, and the role of Medicare and Medicaid are explored, as Reed and Patel discuss how policy can drive greater utilization and trust in biosimilars.

36. How Patient Access, Mistrust Burden Biosimilars 4/25/2025

    Celltrion VP of Medical Affairs Hetal Patel, PharmD, MBA addresses challenges such as access, affordability, and trust in biosimilars in this segment of our Bioprocess Online Live panel discussion Impact Of The Biosimilars Boom. She emphasizes the need for transparent communication, provider-patient alignment, and overcoming misinformation and hesitation.

37. Patient, Payer, Provider, And Pharma Perspectives On Biosimilars 4/25/2025

    In this segment of the Bioprocess Online Live event Impact Of The Biosimilars Boom, Kashiv Biosciences' Associate VP Kaushal Joshi and Biosimilars Forum Executive Director Juliana Reed share payer, provider, patient, and pharmaceutical perspectives on formulary decisions, cost savings potential, barriers to adoption, and how incentives and education can impact uptake. Provider hesitation and the role of real-world evidence are also discussed.

38. Biosimilars Are Booming: The Current Landscape 4/25/2025

    Celltrion VP of Medical Affairs Hetal Patel, PharmD, MBA and Biosimilars Forum Executive Director Juliana Reed kicked off our Bioprocess Online Live panel discussion Impact Of The Biosimilars Boom with an up-to-the-minute review of the biosimilars landscape, including key regulatory aspects, manufacturing complexity, and interchangeability.

39. Helpful Biosafety Testing Innovations Where And When You Need Them 4/24/2025

    Monoclonal antibody manufacturing is advancing to boost efficiency, cut costs, and expand access, driven by innovation, demand, and the rise of biosimilars.

40. ADCs: The Next Phase Of Innovation 4/24/2025

    Explore the pivotal advancements in ADCs that focus on high-DAR, multispecific designs, and novel payloads, while addressing challenges in manufacturability, scalability, regulatory acceptance, and commercial viability.